Article Text

Racecadotril for acute diarrhoea in children: systematic review and meta-analyses
  1. Morris Gordon1,2,
  2. Anthony Akobeng3,4
  1. 1Department of Medical Education, Blackpool Victoria Hospital, Blackpool, UK
  2. 2School of Medicine and Dentistry, University of Central Lancashire, Preston, UK
  3. 3Sidra Medical & Research Center, Doha, Qatar
  4. 4Royal Manchester Children's Hospital, Manchester Academic Health Centre, University of Manchester, Manchester, UK
  1. Correspondence to Dr Morris Gordon, HA106, Harrington Building, School of Medicine and Dentistry, University of Central Lancashire, Preston PR1 2HE, UK; morris{at}betterprescribing.com

Abstract

Objective Racecadotril is an antisecretory agent that can prevent fluid/electrolyte depletion from the bowel as a result of acute diarrhoea without affecting intestinal motility. An up-to-date systematic review is indicated to summarise the evidence on racecadotril for the treatment of acute diarrhoea in children.

Design A Cochrane format systematic review of randomised controlled trials (RCTs). Data extraction and assessment of methodological quality were performed independently by two reviewers. Methodological quality was assessed using the Cochrane risk of bias tool.

Patients Children with acute diarrhoea, as defined by the primary studies.

Interventions RCTs comparing racecadotril with placebo or other interventions.

Main outcome measurs Duration of illness, stool output/volume and adverse events.

Results Seven RCTs were included, five comparing racecadotril with placebo or no intervention, one with pectin/kaolin and one with loperamide. Moderate to high risk of bias was present in all studies. There was no significant difference in efficacy or adverse events between racecadotril and loperamide. A meta-analysis of three studies with 642 participants showed significantly shorter duration of symptoms with racecadotril compared with placebo (mean difference −53.48 h, 95% CI −65.64 to −41.33). A meta-analysis of five studies with 949 participants showed no significant difference in adverse events between racecadotril and placebo (risk ratio 0.99, 95% CI 0.73 to 1.34).

Conclusions There is some evidence that racecadotril is more effective than placebo or no intervention in reducing the duration of illness and stool output in children with acute diarrhoea. However, the overall quality of the evidence is limited due to sparse data, heterogeneity and risk of bias. Racecadotril appears to be safe and well tolerated.

  • Evidence Based Medicine
  • General Paediatrics
  • Gastroenterology

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Supplementary materials

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.